AVTE: Aerovate Therapeutics Inc. Company Current Liabilities

AVTE (Aerovate Therapeutics, Inc) - company brandmark

Aerovate Therapeutics (AVTE) is developing innovative methods to combat pulmonary hypertension. This chart illustrating the asset's market value on GURU.Markets confirms the company's status as a player competing with tech giants through unique patents. The firm is currently revising its R&D strategy following a pause in testing, and the current metric stands at 0.00. A future surge in share prices depends on the trial results of AV-101 and potential contracts with pharmaceutical behemoths.

AVTE (aerovatetx.com) Company Short-Term Debts history from 07/04/2022 to 04/29/2025

Analytical breakdowns for Aerovate Therapeutics, Inc (AVTE)

- current quotes and average value forecast:
Price Chart Aerovate Therapeutics, Inc.|AVTE - Fair Value Consensus
- market capitalization information:
Market Valuation Aerovate Therapeutics, Inc.|AVTE - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Aerovate Therapeutics|AVTE - Book Capitalization|Market Capitalization to Book Value Ratio aerovatetx.com|AVTE - Company Assets
- business debt structure and liquidity details:
Debt to Equity Aerovate Therapeutics|AVTE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Aerovate Therapeutics|AVTE - Company Cumulative Debt|Debt to Book Value Aerovate Therapeutics, Inc.|AVTE - Company Long-Term Debt|Company Short-Term Debts Aerovate Therapeutics|Quick Liquidity Indicator aerovatetx.com
- net income and valuation multiples indicators:
AVTE - Profit After Payment of Taxes
Basic company analysis:Aerovate Therapeutics, Inc. - AVTE
Mass-produced product of Aerovate Therapeutics

To assess the credit quality of Aerovate Therapeutics (AVTE), the analyst examines the company's short-term liabilities, which reflect loan repayment dynamics and the efficiency of working capital management. The stability of this chart confirms the business's solvency, which, combined with an independent sovereign drug development cycle, makes the asset a reliable defensive tool that limits macroeconomic volatility risks during the reinvestment of profits.

Competitor analysis for Aerovate Therapeutics

REGN - Company Short-Term Debt|Company Short-Term Loans and Borrowings IRTC (iRhythm Technologies, Inc.)|LNTH (Lantheus Medical Imaging) - Company Current Liabilities|MLYS: Amount of Current Liabilities|HTFL (HeartFlow Inc) - Company Short-Term Debts|Company Short-Term Debts kestramedical.com|Company Short-Term Debts ESPR|AMRN - Short-Term Debt|Company Short-Term Debt Anteris Technologies AVR|Company Short-Term Loans and Borrowings TNYA|CVRX - Company Short-Term Debt|Short-Term Debt milestonepharma.com|CRDL (cardiolrx.com) - Company Current Liabilities|BEAT (HeartBeam Inc) - Company Short-Term Debt|TENX (Tenax Therapeutics, Inc) - Company Short-Term Debts|Company Short-Term Debts Adagio Medical, Inc.|Company Current Liabilities BCDA (BioCardia, Inc.)|Amount of Current Liabilities VTAK|Company Short-Term Debts ABIO (ARCA Biopharma, Inc.)|Acasti Pharma Inc (ACST) - Short-Term Debt|VERV: Company Current Liabilities|Company Short-Term Loans and Borrowings WINT (Windtree Therapeutics)